Vantage Point

Share this article:
Understanding and measuring what motivates behavior is a central goal for many pharmaceutical market research projects.
Research by psychologists and economists has focused away from carrot-and-stick assumptions about motivation. The findings coming from new models of motivation raise some interesting issues (refer to Daniel Pink's book Drive for a layperson-friendly overview of this body of research). For example:
  • If people enjoy their work, rewards may decrease motivation and reduce out-of-the-box thinking.
  • People are motivated by situations where they feel a sense of purpose—this may outweigh monetary rewards.
  • Companies with policies that allow employees to spend 10-20% of their time doing what they are interested in, relative to their work, see far less turnover and more innovation.
Consider the implications of these findings for market research. First, are we getting the least creative respondents by making the “reward” for research participation totally monetary? While there are clearly legal limits on what can be offered, perhaps we need to revisit the research design itself. Will it motivate at a more intrinsic level if we can tap respondent needs other than through carrot-and-stick?
Second, do we need to create a broader sense of purpose regarding research? If respondents were more engaged, would we get a better breadth of participants, and/or more thoughtful responses? We have found that in patient research where participants feel that their input will help others like them, they proactively go above and beyond the basic requirements.
As motivation models evolve, we will need to consider how this affects our research design.
Donna Kelly is chief consulting officer for GfK HealthCare
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Vantage Point

Email Newsletters

More in Vantage Point

Vantage Point: Payers—the "experts" in healthcare research

Vantage Point: Payers—the "experts" in healthcare research

Access to payers is about knowledge, about understanding what they do in their jobs

Vantage Point: Determining "fair market value"

Vantage Point: Determining "fair market value"

Should pharma formulate a super matrix to determine the FMV of research incentives?

Vantage Point: Marketing Support for Clinical Trials

Vantage Point: Marketing Support for Clinical Trials

Pharmaceutical companies must provide robust marketing support for their clinical trials